FDA approves Endo Pharmaceuticals' Felodipine Extended-release Tablets

Download PDF Copy

Nov 3 2011

Endo Pharmaceuticals (Nasdaq: ENDP) today announced that the U.S. Food and Drug Administration has approved Felodipine Extended-release Tablets USP, 2.5mg, 5mg and 10mg. Qualitest Pharmaceuticals, the generic business unit of Endo Pharmaceuticals, will manufacture and distribute the Felodipine Extended-release Tablets.

Felodipine Extended-release Tablets USP are the generic version of AstraZeneca's Plendil® Extended-release Tablets.

The total sales for Felodipine in the U.S. for the 12 months ended June 30, 2011 were approximately $84 million, according to IMS Health.

SOURCE Endo Pharmaceuticals

Posted in: Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

New study reveals long road to seizure control for people with focal epilepsy

University of Vienna team develops method to measure molecular charges

Gene editing restores hearing and balance in adult mice with DFNA41 deafness

New treatment approach developed to prevent lupus nephritis

CURE GABA-A and Grann Pharmaceuticals announce global partnership to advance rare neurological therapies

Mushrooms deliver nutrition medicine and sustainability solutions in one package

Edible microbeads trap fat to support weight loss

WHO expands global network of trusted medical product regulators

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.